Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 6/20 | 0.46 |
| ▸ | PDE2A | O00408 | 2/20 | 0.43 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.35 |
| ▸ | CTSK | P43235 | 1/20 | 0.34 |
| ▸ | NAAA | Q02083 | 1/20 | 0.34 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.33 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.32 |
| ▸ | ABL1 | P00519 | 1/20 | 0.32 |
| ▸ | MAP2K2 | P36507 | 1/20 | 0.32 |
| ▸ | MAP2K1 | Q02750 | 1/20 | 0.32 |
| ▸ | FAAH | O00519 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30278498 | 0.85 | EPHX2 (0.36) | EPHX2PDE2APTPN1 | |
| SCHEMBL25072879 | 0.85 | EPHX2 (0.36) | EPHX2PDE2APTPN1 | |
| SCHEMBL8532979 | 0.84 | EPHX2 (0.40) | EPHX2PDE2ASLC7A5CTSKNAAA | |
| SCHEMBL16958655 | 0.81 | EPHX2 (0.46) | EPHX2PDE2ASLC7A5CTSKNAAA | |
| SCHEMBL9996574 | 0.81 | PDE2A (0.46) | EPHX2PDE2ASLC7A5CTSKNAAA | |
| SCHEMBL524595 | 0.81 | EPHX2 (0.46) | EPHX2PDE2ASLC7A5 | |
| SCHEMBL2437123 | 0.77 | RAB9A (0.46) | — | |
| SCHEMBL29376896 | 0.76 | EPAS1 (0.33) | EPHX2PTPN1 | |
| SCHEMBL26979442 | 0.76 | EPAS1 (0.33) | EPHX2PTPN1 | |
| SCHEMBL3935869 | 0.75 | ADRA2B (0.41) | EPHX2PTPN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2016086071-A1 | SPECTRALLY ENCODED CONSUMABLE SPECTROMETER APPARATUS AND METHODS | NUEOU, INC. (US) | 2016-06-02 | — | — | WO | disclosed |
| US-8383658-B2 | Isoxazole based neuronal nicotinic receptor ligands and methods of use | ABBOTT LABORATORIES (US) | 2013-02-26 | — | — | US | disclosed |
| US-20090306096-A1 | Novel Isoxazoles and Methods of Use Thereof | ABBOTT LABORATORIES (US) | 2009-12-10 | — | — | US | disclosed |
| US-5725797-A | Silacyclohexane compound, a process for producing the same, and a liquid crystal composition comprising the same | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 1998-03-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090306096-A1 | Novel Isoxazoles and Methods of Use Thereof | XDH, PRDX5, CYP4X1 | EPHX2 357/4885PDE2A 969/4885SLC7A5 3753/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.